A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Plasmodium vivax can form dormant liver stages that reactivate weeks or months following an acute infection. Recurrent infections can be associated with a febrile illness, a cumulative risk of severe anaemia, and even mortality. In co-endemic areas the risk of recurrence after both P. vivax and P. falciparum infections can be over 50% within 3 months. The only drug we have to kill P. vivax hypnozoites is primaquine which is currently given as a 14 day regimen. In Papua a retrospective study found very low effectiveness for unsupervised treatment. If true this has profound effects on treatment policy, suggesting that greater efforts are needed to encourage adherence to treatment.

We propose a cluster randomized, controlled, open label trial to assess the effectiveness of unsupervised versus supervised primaquine treatment in patients with uncomplicated malaria. Since the risk of recurrent P. vivax is high in patients with either P. vivax or P. falciparum, both infections will be included in the study. The study will be conducted in Mimika, in the southern part of Papua Province, Indonesia. Participants will be enrolled at village health posts and provided with schizontocidal treatment plus primaquine radical cure which will be either supervised or unsupervised depending on which cluster the clinic is in. Participants will be followed up for 6 months and assessed in regular intervals for the presence of patent and sub-patent malaria. The outcome of the study will contribute to an improved treatment scheme for uncomplicated malaria in this area.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Menzies School of Health Research
• Collaborator: Timika Research Facility Kompleks RSMM, Timika-Papua, Indonesia
• Treatments: Primaquine

Criteria

Inclusion Criteria:

• Infection with Plasmodium falciparum or P. vivax either alone or mixed

• Age >12 months

• Weight >5kg

• Living in the study clusters

Exclusion Criteria:

• General danger signs or symptoms of severe malaria

• Anaemia, defined as Hb <9g/dl

• G6PD deficiency (as determined by FST)

• Pregnant women as determined by Urine β-HCG pregnancy test

• Known hypersensitivity to any of the drugs given